Biocon and Optimer Sign API Manufacturing Deal

Biotechnology company and manufacturing services provider Biocon (Bangalore, India) says it has entered into a long-term supply agreement with biopharmaceutical company Optimer Pharmaceuticals (San Diego, CA) for the commercial manufacturing of the active pharmaceutical ingredient (API) fidaxomicin - Optimer's lead product candidate for the treatment of clostridium difficile infection (CDI). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of CDI and Optimer has reported positive top-line results from two Phase 3 trials of...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers